Factors associated with seroimmunity against tick borne encephalitis virus 10 years after booster vaccination
► Tick borne encephalitis antibody titers were assessed in 178 and 183 subjects 8 and 10 years post-booster. ► Cumulative seroprotection rates were 86.8% and 77.3% 8 and 10 years post-booster. ► Antibody levels were significantly lower in subjects starting at the age of 50 years. ► Antibody levels w...
Saved in:
Published in | Vaccine Vol. 31; no. 9; pp. 1293 - 1297 |
---|---|
Main Authors | , , , , , , |
Format | Journal Article |
Language | English |
Published |
Kidlington
Elsevier Ltd
18.02.2013
Elsevier Elsevier Limited |
Subjects | |
Online Access | Get full text |
Cover
Loading…
Abstract | ► Tick borne encephalitis antibody titers were assessed in 178 and 183 subjects 8 and 10 years post-booster. ► Cumulative seroprotection rates were 86.8% and 77.3% 8 and 10 years post-booster. ► Antibody levels were significantly lower in subjects starting at the age of 50 years. ► Antibody levels were significantly higher in subjects reporting any kind of allergy. ► A single booster dose was highly effective in subjects who lost protective antibody titers 10 years post-booster.
In a sample of originally 430 healthy adults (18–84 years of age) with documented basic and booster immunization against tick borne encephalitis, cumulative seroprotection rates 8 (n=178) and 10 years (n=183) after the last booster dose were 86.8% and 77.3% according to the neutralization test, respectively. In subjects aged 50 years and older, antibody titers were significantly lower compared to subjects younger than 50 years. History of any allergy but not previous exposure to other flaviviral antigens was associated with higher neutralization titers. In subjects with waning immunity, a single booster dose induced a strong anamnestic antibody response. |
---|---|
AbstractList | In a sample of originally 430 healthy adults (18–84 years of age) with documented basic and booster immunization against tick borne encephalitis, cumulative seroprotection rates 8 (n=178) and 10 years (n=183) after the last booster dose were 86.8% and 77.3% according to the neutralization test, respectively. In subjects aged 50 years and older, antibody titers were significantly lower compared to subjects younger than 50 years. History of any allergy but not previous exposure to other flaviviral antigens was associated with higher neutralization titers. In subjects with waning immunity, a single booster dose induced a strong anamnestic antibody response. ► Tick borne encephalitis antibody titers were assessed in 178 and 183 subjects 8 and 10 years post-booster. ► Cumulative seroprotection rates were 86.8% and 77.3% 8 and 10 years post-booster. ► Antibody levels were significantly lower in subjects starting at the age of 50 years. ► Antibody levels were significantly higher in subjects reporting any kind of allergy. ► A single booster dose was highly effective in subjects who lost protective antibody titers 10 years post-booster. In a sample of originally 430 healthy adults (18–84 years of age) with documented basic and booster immunization against tick borne encephalitis, cumulative seroprotection rates 8 (n=178) and 10 years (n=183) after the last booster dose were 86.8% and 77.3% according to the neutralization test, respectively. In subjects aged 50 years and older, antibody titers were significantly lower compared to subjects younger than 50 years. History of any allergy but not previous exposure to other flaviviral antigens was associated with higher neutralization titers. In subjects with waning immunity, a single booster dose induced a strong anamnestic antibody response. In a sample of originally 430 healthy adults (18-84 years of age) with documented basic and booster immunization against tick borne encephalitis, cumulative seroprotection rates 8 (n=178) and 10 years (n=183) after the last booster dose were 86.8% and 77.3% according to the neutralization test, respectively. In subjects aged 50 years and older, antibody titers were significantly lower compared to subjects younger than 50 years. History of any allergy but not previous exposure to other flaviviral antigens was associated with higher neutralization titers. In subjects with waning immunity, a single booster dose induced a strong anamnestic antibody response.In a sample of originally 430 healthy adults (18-84 years of age) with documented basic and booster immunization against tick borne encephalitis, cumulative seroprotection rates 8 (n=178) and 10 years (n=183) after the last booster dose were 86.8% and 77.3% according to the neutralization test, respectively. In subjects aged 50 years and older, antibody titers were significantly lower compared to subjects younger than 50 years. History of any allergy but not previous exposure to other flaviviral antigens was associated with higher neutralization titers. In subjects with waning immunity, a single booster dose induced a strong anamnestic antibody response. Highlights ► Tick borne encephalitis antibody titers were assessed in 178 and 183 subjects 8 and 10 years post-booster. ► Cumulative seroprotection rates were 86.8% and 77.3% 8 and 10 years post-booster. ► Antibody levels were significantly lower in subjects starting at the age of 50 years. ► Antibody levels were significantly higher in subjects reporting any kind of allergy. ► A single booster dose was highly effective in subjects who lost protective antibody titers 10 years post-booster. Highlights * Tick borne encephalitis antibody titers were assessed in 178 and 183 subjects 8 and 10 years post-booster. * Cumulative seroprotection rates were 86.8% and 77.3% 8 and 10 years post-booster. * Antibody levels were significantly lower in subjects starting at the age of 50 years. * Antibody levels were significantly higher in subjects reporting any kind of allergy. * A single booster dose was highly effective in subjects who lost protective antibody titers 10 years post-booster. In a sample of originally 430 healthy adults (18a84 years of age) with documented basic and booster immunization against tick borne encephalitis, cumulative seroprotection rates 8 (n = 178) and 10 years (n = 183) after the last booster dose were 86.8% and 77.3% according to the neutralization test, respectively. In subjects aged 50 years and older, antibody titers were significantly lower compared to subjects younger than 50 years. History of any allergy but not previous exposure to other flaviviral antigens was associated with higher neutralization titers. In subjects with waning immunity, a single booster dose induced a strong anamnestic antibody response. |
Author | Brodtraeger, Natascha Kollaritsch, Herwig Kundi, Michael Seidl-Friedrich, Claudia Paulke-Korinek, Maria Laaber, Brigitte Wiedermann, Ursula |
Author_xml | – sequence: 1 givenname: Maria surname: Paulke-Korinek fullname: Paulke-Korinek, Maria organization: Department of Specific Prophylaxis and Tropical Medicine, Medical University of Vienna, Kinderspitalgasse 15, A-1090 Vienna, Austria – sequence: 2 givenname: Michael surname: Kundi fullname: Kundi, Michael organization: Institute of Environmental Health, Center for Public Health, Medical University of Vienna, Kinderspitalgasse 15, A-1090 Vienna, Austria – sequence: 3 givenname: Brigitte surname: Laaber fullname: Laaber, Brigitte organization: Department of Specific Prophylaxis and Tropical Medicine, Medical University of Vienna, Kinderspitalgasse 15, A-1090 Vienna, Austria – sequence: 4 givenname: Natascha surname: Brodtraeger fullname: Brodtraeger, Natascha organization: Department of Specific Prophylaxis and Tropical Medicine, Medical University of Vienna, Kinderspitalgasse 15, A-1090 Vienna, Austria – sequence: 5 givenname: Claudia surname: Seidl-Friedrich fullname: Seidl-Friedrich, Claudia organization: Department of Specific Prophylaxis and Tropical Medicine, Medical University of Vienna, Kinderspitalgasse 15, A-1090 Vienna, Austria – sequence: 6 givenname: Ursula surname: Wiedermann fullname: Wiedermann, Ursula organization: Department of Specific Prophylaxis and Tropical Medicine, Medical University of Vienna, Kinderspitalgasse 15, A-1090 Vienna, Austria – sequence: 7 givenname: Herwig surname: Kollaritsch fullname: Kollaritsch, Herwig email: herwig.kollaritsch@meduniwien.ac.at organization: Department of Specific Prophylaxis and Tropical Medicine, Medical University of Vienna, Kinderspitalgasse 15, A-1090 Vienna, Austria |
BackLink | http://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=27110613$$DView record in Pascal Francis https://www.ncbi.nlm.nih.gov/pubmed/23306371$$D View this record in MEDLINE/PubMed |
BookMark | eNqNkl9rFDEUxQep2G31I6gDIviya_5MJhmKihSrQsGHVvAtZDI3bbYzyZpkVvbbm-luKSzICoH78rvnntx7Tooj5x0UxUuMFhjh-v1ysVZaWwcLgjBZ5Ic4e1LMsOB0ThgWR8UMkbqaVxj9Oi5OYlwihBjFzbPimFCKasrxrBgulE4-xFLF6LVVCbryj023ZYTg7TCMzqZNqW6UdTGVyeq7svXBQQlOw-pW9TbZWK5tGGOJUbkBNWmZBCFzPk5161Ml693z4qlRfYQXu3paXF98uT7_Nr_88fX7-efLua4JSfOu0w3h0DbAW-BVTZmgRovOdECwBtSYhmFuOkLalqtacW06ZLgRjPGqBXpavNvKroL_PUJMcrBRQ98rB36MEtei5qSpMDuM0kpUDaooOowSUTdVVfFJ9c0euvRjcPnLeTZhDRWkaTL1akeN7QCdXAU7qLCRD9fJwNsdoKJWvQnKaRsfOY4xqjHN3NmW08HHGMBIbdP9wlNQtpcYySkzcil3mZFTZrJhie7Nsr3uhwGH-l5v-4zyUt2E7OznVQYYQpgLJkgmPm0JyLdeWwgyajsFp7MBdJKdtwdnfNxT0L11Ni_jDjYQH7cqY26QV1Pip8DjLCJylrLAh38L_IeBvx3oEVc |
CODEN | VACCDE |
CitedBy_id | crossref_primary_10_1371_journal_pone_0247216 crossref_primary_10_1016_j_vaccine_2014_01_072 crossref_primary_10_1111_ene_13356 crossref_primary_10_1093_femspd_ftu002 crossref_primary_10_1016_j_tmaid_2020_101876 crossref_primary_10_1017_S0950268821000194 crossref_primary_10_1080_21645515_2015_1093263 crossref_primary_10_1371_journal_pone_0257721 crossref_primary_10_1371_journal_pone_0100860 crossref_primary_10_3390_vaccines10081294 crossref_primary_10_7774_cevr_2025_14_e8 crossref_primary_10_1080_21645515_2020_1757990 crossref_primary_10_1093_cid_ciz176 crossref_primary_10_3389_fimmu_2024_1352720 crossref_primary_10_31631_2073_3046_2018_17_5_78_88 crossref_primary_10_33442_978_981_14_0914_1_14 crossref_primary_10_31631_2073_3046_2016_15_2_72_76 crossref_primary_10_1016_j_ttbdis_2013_06_001 crossref_primary_10_1016_j_ttbdis_2021_101779 crossref_primary_10_31631_2073_3046_2025_24_1_31_41 crossref_primary_10_1016_j_vaccine_2016_07_029 crossref_primary_10_1371_journal_pone_0140545 crossref_primary_10_1016_j_vaccine_2015_05_037 crossref_primary_10_1016_j_vaccine_2015_12_057 crossref_primary_10_1586_14760584_2015_985661 crossref_primary_10_1002_jmv_25316 crossref_primary_10_1016_j_vaccine_2018_03_076 crossref_primary_10_18821_0507_4088_2018_63_1_36_40 crossref_primary_10_21101_cejph_a5271 crossref_primary_10_1128_JCM_02680_13 crossref_primary_10_33442_26613980_14_6 crossref_primary_10_1016_j_antiviral_2019_01_014 crossref_primary_10_1136_bmjopen_2022_061228 crossref_primary_10_1016_j_vaccine_2022_01_022 crossref_primary_10_1016_j_vaccine_2013_05_093 crossref_primary_10_1016_j_ttbdis_2013_04_005 crossref_primary_10_33442_26613980_14_5 crossref_primary_10_33442_26613980_14_4 |
Cites_doi | 10.1111/j.1399-3038.2005.00331.x 10.1099/vir.0.031641-0 10.1007/s10354-010-0758-5 10.1111/j.1469-0691.2012.03944.x 10.1016/j.vaccine.2008.08.056 10.1016/S0140-6736(98)05104-6 10.1586/erv.12.86 10.1016/j.vaccine.2007.08.024 10.1016/j.vaccine.2004.07.002 10.1016/j.vaccine.2005.01.085 10.1016/j.idc.2008.03.013 10.1016/0264-410X(91)90315-W 10.1586/14760584.7.5.589 10.1128/JVI.00080-06 10.1016/j.vaccine.2011.07.089 10.1016/j.vaccine.2009.09.068 10.1016/j.vaccine.2006.06.037 10.1371/journal.pone.0034145 10.1002/(SICI)1096-9071(199601)48:1<102::AID-JMV16>3.0.CO;2-I 10.1046/j.1365-2249.1997.4311446.x 10.1016/j.vaccine.2007.01.116 10.1016/S0264-410X(02)00819-8 10.1093/infdis/jir122 10.4161/hv.5.8.8571 10.1016/S0264-410X(02)00813-7 10.1111/j.0105-2896.2006.00403.x 10.2807/ese.14.36.19325-en 10.1016/j.vaccine.2008.11.082 10.1016/j.vaccine.2006.01.007 10.1016/j.vaccine.2006.08.044 10.2807/ese.13.26.18916-en 10.1016/j.vaccine.2004.01.041 |
ContentType | Journal Article |
Copyright | 2013 Elsevier Ltd Elsevier Ltd 2014 INIST-CNRS Copyright © 2013 Elsevier Ltd. All rights reserved. Copyright Elsevier Limited Feb 18, 2013 |
Copyright_xml | – notice: 2013 Elsevier Ltd – notice: Elsevier Ltd – notice: 2014 INIST-CNRS – notice: Copyright © 2013 Elsevier Ltd. All rights reserved. – notice: Copyright Elsevier Limited Feb 18, 2013 |
DBID | FBQ AAYXX CITATION IQODW CGR CUY CVF ECM EIF NPM 3V. 7QL 7RV 7T2 7T5 7U9 7X7 7XB 88C 88E 8AO 8C1 8FE 8FH 8FI 8FJ 8FK 8G5 ABUWG AEUYN AFKRA AZQEC BBNVY BENPR BHPHI C1K CCPQU DWQXO FYUFA GHDGH GNUQQ GUQSH H94 HCIFZ K9- K9. KB0 LK8 M0R M0S M0T M1P M2O M7N M7P MBDVC NAPCQ PHGZM PHGZT PJZUB PKEHL PPXIY PQEST PQGLB PQQKQ PQUKI PRINS Q9U 7X8 7S9 L.6 |
DOI | 10.1016/j.vaccine.2012.12.075 |
DatabaseName | AGRIS CrossRef Pascal-Francis Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed ProQuest Central (Corporate) Bacteriology Abstracts (Microbiology B) Nursing & Allied Health Database Health and Safety Science Abstracts (Full archive) Immunology Abstracts Virology and AIDS Abstracts ProQuest Health & Medical Collection ProQuest Central (purchase pre-March 2016) Healthcare Administration Database (Alumni) Medical Database (Alumni Edition) ProQuest Pharma Collection Public Health Database (Proquest) ProQuest SciTech Collection ProQuest Natural Science Journals Hospital Premium Collection Hospital Premium Collection (Alumni Edition) ProQuest Central (Alumni) (purchase pre-March 2016) ProQuest Research Library ProQuest Central (Alumni) ProQuest One Sustainability (subscription) ProQuest Central UK/Ireland ProQuest Central Essentials Biological Science Collection ProQuest Central Natural Science Collection Environmental Sciences and Pollution Management ProQuest One Community College ProQuest Central Korea Health Research Premium Collection Health Research Premium Collection (Alumni) ProQuest Central Student Research Library Prep AIDS and Cancer Research Abstracts ProQuest SciTech Premium Collection Consumer Health Database ProQuest Health & Medical Complete (Alumni) Nursing & Allied Health Database (Alumni Edition) Biological Sciences Consumer Health Database Health & Medical Collection (Alumni) Healthcare Administration Database (Proquest) Proquest Medical Database ProQuest Research Library Algology Mycology and Protozoology Abstracts (Microbiology C) Biological Science Database Research Library (Corporate) Nursing & Allied Health Premium ProQuest Central Premium ProQuest One Academic ProQuest Health & Medical Research Collection ProQuest One Academic Middle East (New) ProQuest One Health & Nursing ProQuest One Academic Eastern Edition (DO NOT USE) ProQuest One Applied & Life Sciences ProQuest One Academic ProQuest One Academic UKI Edition ProQuest Central China ProQuest Central Basic MEDLINE - Academic AGRICOLA AGRICOLA - Academic |
DatabaseTitle | CrossRef MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) Research Library Prep ProQuest Central Student ProQuest Central Essentials SciTech Premium Collection ProQuest Central China Environmental Sciences and Pollution Management ProQuest One Applied & Life Sciences ProQuest One Sustainability Health Research Premium Collection Natural Science Collection Health & Medical Research Collection Biological Science Collection ProQuest Central (New) ProQuest Medical Library (Alumni) Virology and AIDS Abstracts ProQuest Biological Science Collection ProQuest Family Health ProQuest One Academic Eastern Edition ProQuest Hospital Collection Health Research Premium Collection (Alumni) Biological Science Database ProQuest Hospital Collection (Alumni) Nursing & Allied Health Premium ProQuest Health & Medical Complete ProQuest One Academic UKI Edition ProQuest Health Management (Alumni Edition) ProQuest Nursing & Allied Health Source (Alumni) ProQuest One Academic ProQuest One Academic (New) ProQuest One Academic Middle East (New) ProQuest Health & Medical Complete (Alumni) ProQuest Central (Alumni Edition) ProQuest One Community College ProQuest One Health & Nursing Research Library (Alumni Edition) ProQuest Natural Science Collection ProQuest Pharma Collection ProQuest Family Health (Alumni Edition) ProQuest Central ProQuest Health & Medical Research Collection Health and Medicine Complete (Alumni Edition) ProQuest Central Korea Bacteriology Abstracts (Microbiology B) Algology Mycology and Protozoology Abstracts (Microbiology C) AIDS and Cancer Research Abstracts ProQuest Research Library Health & Safety Science Abstracts ProQuest Public Health ProQuest Central Basic ProQuest Health Management ProQuest Nursing & Allied Health Source ProQuest SciTech Collection ProQuest Medical Library Immunology Abstracts ProQuest Central (Alumni) MEDLINE - Academic AGRICOLA AGRICOLA - Academic |
DatabaseTitleList | AGRICOLA MEDLINE - Academic Research Library Prep MEDLINE AIDS and Cancer Research Abstracts |
Database_xml | – sequence: 1 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: EIF name: MEDLINE url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search sourceTypes: Index Database – sequence: 3 dbid: BENPR name: ProQuest Central url: https://www.proquest.com/central sourceTypes: Aggregation Database – sequence: 4 dbid: FBQ name: AGRIS url: http://www.fao.org/agris/Centre.asp?Menu_1ID=DB&Menu_2ID=DB1&Language=EN&Content=http://www.fao.org/agris/search?Language=EN sourceTypes: Publisher |
DeliveryMethod | fulltext_linktorsrc |
Discipline | Medicine Veterinary Medicine Biology Pharmacy, Therapeutics, & Pharmacology |
EISSN | 1873-2518 |
EndPage | 1297 |
ExternalDocumentID | 3500387671 23306371 27110613 10_1016_j_vaccine_2012_12_075 US201500178582 S0264410X12018622 1_s2_0_S0264410X12018622 |
Genre | Research Support, Non-U.S. Gov't Journal Article |
GeographicLocations | Austria Europe |
GeographicLocations_xml | – name: Austria – name: Europe |
GroupedDBID | --- --K --M .1- .FO .~1 0R~ 123 1B1 1P~ 1RT 1~. 1~5 4.4 457 4G. 53G 5RE 5VS 7-5 71M 7RV 7X7 88E 8AO 8C1 8FE 8FH 8FI 8FJ 8G5 8P~ 9JM AAAJQ AABNK AAEDT AAEDW AAHBH AAIKJ AAKOC AALRI AAOAW AAQFI AARKO AATTM AAXKI AAXUO AAYWO ABBQC ABFNM ABFRF ABJNI ABKYH ABMAC ABMZM ABRWV ABUWG ABWVN ABXDB ACDAQ ACGFO ACGFS ACIEU ACIUM ACPRK ACRLP ACVFH ADBBV ADCNI ADEZE ADFRT AEBSH AEFWE AEIPS AEKER AENEX AEUPX AEUYN AEVXI AEXOQ AFKRA AFPUW AFRAH AFRHN AFTJW AFXIZ AGCQF AGEKW AGGSO AGUBO AGYEJ AHMBA AIEXJ AIIUN AIKHN AITUG AJRQY AJUYK AKBMS AKRWK AKYEP ALMA_UNASSIGNED_HOLDINGS AMRAJ ANKPU ANZVX AQUVI AXJTR AZQEC BBNVY BENPR BHPHI BKEYQ BKNYI BKOJK BLXMC BNPGV BPHCQ BVXVI CCPQU CJTIS CNWQP CS3 DWQXO EBS EFJIC EFKBS EJD EO8 EO9 EP2 EP3 F5P FDB FIRID FNPLU FYGXN FYUFA G-Q GBLVA GNUQQ GUQSH HCIFZ HMCUK IHE J1W K9- KOM L7B LK8 LUGTX LW9 M0R M0T M1P M29 M2O M41 M7P MO0 N9A NAPCQ O-L O9- O9~ OAUVE OK0 OZT P-8 P-9 P2P PC. PHGZM PHGZT PJZUB PPXIY PQGLB PQQKQ PROAC PSQYO PUEGO Q38 ROL RPZ SAB SCC SDF SDG SDP SES SNL SPCBC SSH SSI SSZ T5K UKHRP UV1 WH7 WOW Z5R ~G- .GJ 29Q 3V. AACTN AAQXK ACRPL ADMUD ADNMO ADVLN AFCTW AFJKZ AFKWA AGHFR AHHHB AJOXV ALIPV AMFUW ASPBG AVWKF AZFZN FEDTE FGOYB G-2 HEJ HLV HMG HMK HMO HVGLF HX~ HZ~ R2- RIG SAE SEW SIN SVS WUQ XPP ZGI ZXP AAIAV ABLVK ABYKQ AESVU AJBFU EFLBG LCYCR QYZTP ABPIF ABPTK FBQ AAYXX ACMHX ADSLC AGQPQ AGRNS AGWPP AIGII APXCP CITATION IQODW CGR CUY CVF ECM EIF NPM 7QL 7T2 7T5 7U9 7XB 8FK C1K H94 K9. M7N MBDVC PKEHL PQEST PQUKI PRINS Q9U 7X8 7S9 L.6 |
ID | FETCH-LOGICAL-c622t-ddc927eb9e7be7463583fc8dfde21ce09f9517fd22bb7a6a7cfd0f7f85574be3 |
IEDL.DBID | 7X7 |
ISSN | 0264-410X 1873-2518 |
IngestDate | Fri Jul 11 16:24:16 EDT 2025 Fri Jul 11 01:59:29 EDT 2025 Tue Aug 05 09:32:51 EDT 2025 Wed Aug 13 04:13:54 EDT 2025 Mon Jul 21 06:05:47 EDT 2025 Mon Jul 21 09:15:27 EDT 2025 Tue Jul 01 03:38:02 EDT 2025 Thu Apr 24 23:06:01 EDT 2025 Wed Dec 27 19:27:02 EST 2023 Fri Feb 23 02:26:53 EST 2024 Sun Feb 23 10:19:12 EST 2025 Tue Aug 26 17:46:42 EDT 2025 |
IsPeerReviewed | true |
IsScholarly | true |
Issue | 9 |
Keywords | Booster properties Long-term Antibody persistence Tick borne encephalitis Immunization schedule Follow-up Nervous system diseases Immunization Antibody Booster vaccination Vaccine Flavivirus Cerebral disorder Infection Tick borne encephalitis group virus Virus Viral disease Arbovirus disease Central nervous system disease Flaviviridae Tick borne encephalitis virus |
Language | English |
License | https://www.elsevier.com/tdm/userlicense/1.0 CC BY 4.0 Copyright © 2013 Elsevier Ltd. All rights reserved. |
LinkModel | DirectLink |
MergedId | FETCHMERGED-LOGICAL-c622t-ddc927eb9e7be7463583fc8dfde21ce09f9517fd22bb7a6a7cfd0f7f85574be3 |
Notes | http://dx.doi.org/10.1016/j.vaccine.2012.12.075 ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 14 content type line 23 ObjectType-Article-2 ObjectType-Feature-1 |
PMID | 23306371 |
PQID | 1625938299 |
PQPubID | 105530 |
PageCount | 5 |
ParticipantIDs | proquest_miscellaneous_1686729415 proquest_miscellaneous_1348490430 proquest_miscellaneous_1286944475 proquest_journals_1625938299 pubmed_primary_23306371 pascalfrancis_primary_27110613 crossref_citationtrail_10_1016_j_vaccine_2012_12_075 crossref_primary_10_1016_j_vaccine_2012_12_075 fao_agris_US201500178582 elsevier_sciencedirect_doi_10_1016_j_vaccine_2012_12_075 elsevier_clinicalkeyesjournals_1_s2_0_S0264410X12018622 elsevier_clinicalkey_doi_10_1016_j_vaccine_2012_12_075 |
ProviderPackageCode | CITATION AAYXX |
PublicationCentury | 2000 |
PublicationDate | 2013-02-18 |
PublicationDateYYYYMMDD | 2013-02-18 |
PublicationDate_xml | – month: 02 year: 2013 text: 2013-02-18 day: 18 |
PublicationDecade | 2010 |
PublicationPlace | Kidlington |
PublicationPlace_xml | – name: Kidlington – name: Netherlands |
PublicationTitle | Vaccine |
PublicationTitleAlternate | Vaccine |
PublicationYear | 2013 |
Publisher | Elsevier Ltd Elsevier Elsevier Limited |
Publisher_xml | – name: Elsevier Ltd – name: Elsevier – name: Elsevier Limited |
References | Plentz, Jilg, Schwarz, Kuhr, Zent (bib0065) 2009; 27 Weinberger, Grubeck-Loebenstein (bib0125) 2012; 18 Fomsgaard A, Christiansen C, Bodker R. First identification of tick-borne encephalitis in Denmark outside of Bornholm. Euro Surveill 2009;14(36):pii=19325. Available from Jelenik, Keller, Briggs, Günther, Haglund, Hudeckova (bib0045) 2010; 160 Kaml, Weiskirchner, Keller, Luft, Hoster, Hasford (bib0100) 2006; 24 Kunz (bib0035) 2003; 21 Heinz, Holzmann, Essl, Kundi (bib0040) 2007; 25 Loew-Baselli, Poellabauer, Pavlova, Fritsch, Firth, Petermann (bib0110) 2011; 29 Mansfield, Horton, Johnson, Li, Barrett, Smith (bib0155) 2011; 92 World Health Organization (bib0030) 2011; 24 Klockmann, Bock, Kwasny, Praus, Cihlová, Tomková (bib0095) 1991; 9 Süss (bib0015) 2008; 13. Rendi-Wagner, Shouval, Genton, Lurie, Rumke, Boland (bib0140) 2006; 24 Rendi-Wagner, Kundi, Zent, Banzhoff, Jaehnig, Stemberger (bib0070) 2004; 23 Prescott, Macaubas, Smallacombe, Holt, Sly, Holt (bib0165) 1999; 353 Hainz, Jenewein, Asch, Pfeiffer, Berger, Grubeck-Loebenstein (bib0105) 2005; 23 Orlinger, Hofmeister, Fritz, Holzer, Falkner, Unger (bib0150) 2011; 203 Rendi-Wagner, Paulke-Korinek, Kundi, Wiedermann, Laaber, Kollaritsch (bib0075) 2007; 25 Paulke-Korinek, Rendi-Wagner, Kundi, Laaber, Wiedermann, Kollaritsch (bib0060) 2009; 27 Holzmann, Kundi, Stiasny, Clement, McKenna, Kunz (bib0085) 1996; 48 Blanco-Quiros, Garcia-Marcos, Garrote, Martinez-Torres, Leon (bib0160) 2005; 16 Schuller, Klade, Heinz, Kollaritsch, Rendi-Wagner, Jilma (bib0145) 2008; 26 Stiasny, Kiermayr, Holzmann, Heinz (bib0080) 2006; 80 Kaiser (bib0010) 2008; 22 Holzmann (bib0130) 2003; 21 [accessed 15.10.12]. Loew-Baselli, Poellabauer, Pavlova, Fritsch, Koska, Bobrovsky (bib0115) 2009; 5 Kreil, Burger, Bachmann, Fraiss, Eibl (bib0090) 1997; 110 Stiasny, Aberle, Keller, Grubeck-Loebenstein, Heinz (bib0120) 2012; 7 Rendi-Wagner, Kundi, Zent, Dvorak, Jaehnig, Holzmann (bib0050) 2004; 22 Abbas, Lichtman, Pillai (bib0170) 2007 Schosser, Kaiser, Mansmann, Heininger (bib0055) 2009 Lanzavecchia, Bernasconi, Traggiai, Ruprecht, Corti, Sallusto (bib0175) 2006; 211 Kollaritsch, Paulke-Korinek, Holzmann, Hombach, Bjorvatn, Barrett (bib0020) 2012; 11 Rendi-Wagner, Korinek, Winkler, Kundi, Kollaritsch, Wiedermann (bib0135) 2007; 25 Rendi-Wagner (bib0005) 2008; 7 Loew-Baselli (10.1016/j.vaccine.2012.12.075_bib0115) 2009; 5 Blanco-Quiros (10.1016/j.vaccine.2012.12.075_bib0160) 2005; 16 10.1016/j.vaccine.2012.12.075_bib0025 Lanzavecchia (10.1016/j.vaccine.2012.12.075_bib0175) 2006; 211 Schosser (10.1016/j.vaccine.2012.12.075_bib0055) 2009 Rendi-Wagner (10.1016/j.vaccine.2012.12.075_bib0005) 2008; 7 Rendi-Wagner (10.1016/j.vaccine.2012.12.075_bib0140) 2006; 24 Plentz (10.1016/j.vaccine.2012.12.075_bib0065) 2009; 27 Kollaritsch (10.1016/j.vaccine.2012.12.075_bib0020) 2012; 11 Prescott (10.1016/j.vaccine.2012.12.075_bib0165) 1999; 353 Jelenik (10.1016/j.vaccine.2012.12.075_bib0045) 2010; 160 Klockmann (10.1016/j.vaccine.2012.12.075_bib0095) 1991; 9 Holzmann (10.1016/j.vaccine.2012.12.075_bib0085) 1996; 48 Abbas (10.1016/j.vaccine.2012.12.075_bib0170) 2007 Orlinger (10.1016/j.vaccine.2012.12.075_bib0150) 2011; 203 Rendi-Wagner (10.1016/j.vaccine.2012.12.075_bib0050) 2004; 22 Rendi-Wagner (10.1016/j.vaccine.2012.12.075_bib0135) 2007; 25 Mansfield (10.1016/j.vaccine.2012.12.075_bib0155) 2011; 92 Stiasny (10.1016/j.vaccine.2012.12.075_bib0080) 2006; 80 Heinz (10.1016/j.vaccine.2012.12.075_bib0040) 2007; 25 Holzmann (10.1016/j.vaccine.2012.12.075_bib0130) 2003; 21 Rendi-Wagner (10.1016/j.vaccine.2012.12.075_bib0075) 2007; 25 Paulke-Korinek (10.1016/j.vaccine.2012.12.075_bib0060) 2009; 27 Kunz (10.1016/j.vaccine.2012.12.075_bib0035) 2003; 21 Kreil (10.1016/j.vaccine.2012.12.075_bib0090) 1997; 110 Stiasny (10.1016/j.vaccine.2012.12.075_bib0120) 2012; 7 Rendi-Wagner (10.1016/j.vaccine.2012.12.075_bib0070) 2004; 23 Süss (10.1016/j.vaccine.2012.12.075_bib0015) 2008; 13. Kaiser (10.1016/j.vaccine.2012.12.075_bib0010) 2008; 22 Kaml (10.1016/j.vaccine.2012.12.075_bib0100) 2006; 24 Weinberger (10.1016/j.vaccine.2012.12.075_bib0125) 2012; 18 Schuller (10.1016/j.vaccine.2012.12.075_bib0145) 2008; 26 World Health Organization (10.1016/j.vaccine.2012.12.075_bib0030) 2011; 24 Hainz (10.1016/j.vaccine.2012.12.075_bib0105) 2005; 23 Loew-Baselli (10.1016/j.vaccine.2012.12.075_bib0110) 2011; 29 |
References_xml | – volume: 27 start-page: 7027 year: 2009 end-page: 7030 ident: bib0060 article-title: Booster vaccinations against tick-borne encephalitis: 6 years follow-up indicates long-term protection publication-title: Vaccine – volume: 21 start-page: S50 year: 2003 end-page: S55 ident: bib0035 article-title: TBE vaccination and the Austrian experience publication-title: Vaccine – volume: 23 start-page: 3232 year: 2005 end-page: 3235 ident: bib0105 article-title: Insufficient protection for healthy elderly adults by tetanus and TBE vaccines publication-title: Vaccine – volume: 23 start-page: 427 year: 2004 end-page: 434 ident: bib0070 article-title: Immunogenicity and safety of a booster vaccination against tick-borne encephalitis more than 3 years following the last immunisation publication-title: Vaccine – volume: 18 start-page: 100 year: 2012 end-page: 108 ident: bib0125 article-title: Vaccines for the elderly publication-title: Clin Microbiol Infect – volume: 11 start-page: 1103 year: 2012 end-page: 1119 ident: bib0020 article-title: Vaccines and vaccination against tick-borne encephalitis publication-title: Expert Rev Vaccines – volume: 29 start-page: 7307 year: 2011 end-page: 7319 ident: bib0110 article-title: Prevention of tick-borne encephalitis by FSME-IMMUN vaccines: review of a clinical development programme publication-title: Vaccine – volume: 203 start-page: 1556 year: 2011 end-page: 1564 ident: bib0150 article-title: A tick-borne encephalitis vaccine based on the European prototype strain induces broadly reactive cross-neutralizing antibodies in humans publication-title: J Infect Dis – volume: 25 start-page: 927 year: 2007 end-page: 931 ident: bib0135 article-title: Persistence of seroprotection 10 years after primary hepatitis A vaccination in an unselected study population publication-title: Vaccine – year: 2009 ident: bib0055 article-title: Seropositivity before and seroprotection after a booster vaccination with FSME-Immun adults in subjects with a time interval of >4.5 years since the last TBE vaccination publication-title: International Jena Symposium on Tick Borne Diseases – volume: 353 start-page: 196 year: 1999 end-page: 200 ident: bib0165 article-title: Development of allergen-specific T-cell memory in atopic and normal children publication-title: Lancet – volume: 25 start-page: 5097 year: 2007 end-page: 5101 ident: bib0075 article-title: Antibody persistence following booster vaccination against tick-borne encephalitis: 3-year post-booster follow-up publication-title: Vaccine – volume: 26 start-page: 6151 year: 2008 end-page: 6156 ident: bib0145 article-title: Effect of pre-existing anti-tick-borne encephalitis virus immunity on neutralising antibody response to the Vero cell-derived, inactivated Japanese encephalitis virus vaccine candidate IC51 publication-title: Vaccine – reference: Fomsgaard A, Christiansen C, Bodker R. First identification of tick-borne encephalitis in Denmark outside of Bornholm. Euro Surveill 2009;14(36):pii=19325. Available from: – volume: 25 start-page: 7559 year: 2007 end-page: 7567 ident: bib0040 article-title: Field effectiveness of vaccination against tick-borne encephalitis publication-title: Vaccine – volume: 211 start-page: 303 year: 2006 end-page: 309 ident: bib0175 article-title: Understanding and making use of human memory B cells publication-title: Immunol Rev – volume: 13. year: 2008 ident: bib0015 article-title: Tick-borne encephalitis in Europe and beyond—the epidemiological situation as of 2007 publication-title: Euro Surveill – volume: 80 start-page: 9557 year: 2006 end-page: 9568 ident: bib0080 article-title: Cryptic properties of a cluster of dominant flavivirus cross-reactive antigenic sites publication-title: J Virol – volume: 24 start-page: 6808 year: 2006 end-page: 6811 ident: bib0100 article-title: Booster vaccination in the elderly: their success depends on the vaccine type applied earlier in life as well as on pre-vaccination antibody titers publication-title: Vaccine – volume: 92 start-page: 2821 year: 2011 end-page: 2829 ident: bib0155 article-title: Flavivirus-induced antibody cross-reactivity publication-title: J Gen Virol – reference: [accessed 15.10.12]. – year: 2007 ident: bib0170 article-title: Cellular and molecular immunology – volume: 7 start-page: e34145 year: 2012 ident: bib0120 article-title: Age affects quantity but not quality of antibody responses after vaccination with an inactivated flavivirus vaccine against tick-borne encephalitis publication-title: PLoS ONE – volume: 24 start-page: 2781 year: 2006 end-page: 2789 ident: bib0140 article-title: Comparative immunogenicity of a PreS/S hepatitis B vaccine in non- and low responders to conventional vaccine publication-title: Vaccine – volume: 21 start-page: S36 year: 2003 end-page: S40 ident: bib0130 article-title: Diagnosis of tick-borne encephalitis publication-title: Vaccine – volume: 9 start-page: 42 year: 1991 end-page: 46 ident: bib0095 article-title: Humoral immunity against tick-borne encephalitis virus following manifest disease and active immunization publication-title: Vaccine – volume: 110 start-page: 358 year: 1997 end-page: 361 ident: bib0090 article-title: Antibodies protect mice against challenge with tick-borne encephalitis virus (TBEV)-infected macrophages publication-title: Clin Exp Immunol – volume: 22 start-page: 561 year: 2008 end-page: 575 ident: bib0010 article-title: Tick-borne encephalitis publication-title: Infect Dis Clin North Am – volume: 22 start-page: 2743 year: 2004 end-page: 2749 ident: bib0050 article-title: Persistence of protective immunity following vaccination against tick-borne encephalitis—longer than expected? publication-title: Vaccine – volume: 48 start-page: 102 year: 1996 end-page: 107 ident: bib0085 article-title: Correlation between ELISA, hemagglutination inhibition, and neutralization tests after vaccination against tick-borne encephalitis publication-title: J Med Virol – volume: 160 start-page: 247 year: 2010 end-page: 251 ident: bib0045 article-title: Congress report: tick-borne encephalitis and golden agers: position paper of the International Scientific Working Group on Tick-borne Encephalitis (ISW-TBE) publication-title: Wien Med Wochenschr – volume: 27 start-page: 853 year: 2009 end-page: 856 ident: bib0065 article-title: Long-term persistence of tick-borne encephalitis antibodies in adults 5 years after booster vaccination with Encepur Adults publication-title: Vaccine – volume: 24 start-page: 241 year: 2011 end-page: 256 ident: bib0030 article-title: Vaccines against tick-borne encephalitis: WHO position paper publication-title: WER – volume: 5 start-page: 551 year: 2009 end-page: 556 ident: bib0115 article-title: Seropersistence of tick-borne encephalitis antibodies, safety and booster response to FSME-IMMUN 0.5 publication-title: Hum Vaccines – volume: 7 start-page: 589 year: 2008 end-page: 596 ident: bib0005 article-title: Advances in vaccination against tick-borne encephalitis publication-title: Expert Rev Vaccines – volume: 16 start-page: 637 year: 2005 end-page: 640 ident: bib0160 article-title: Antibody levels to publication-title: Pediatr Allergy Immunol – volume: 16 start-page: 637 issue: 8 year: 2005 ident: 10.1016/j.vaccine.2012.12.075_bib0160 article-title: Antibody levels to Bordetella pertussis in 10-yr-old children with atopy and atopic asthma publication-title: Pediatr Allergy Immunol doi: 10.1111/j.1399-3038.2005.00331.x – volume: 92 start-page: 2821 issue: Pt 12 year: 2011 ident: 10.1016/j.vaccine.2012.12.075_bib0155 article-title: Flavivirus-induced antibody cross-reactivity publication-title: J Gen Virol doi: 10.1099/vir.0.031641-0 – volume: 160 start-page: 247 issue: 9–10 year: 2010 ident: 10.1016/j.vaccine.2012.12.075_bib0045 article-title: Congress report: tick-borne encephalitis and golden agers: position paper of the International Scientific Working Group on Tick-borne Encephalitis (ISW-TBE) publication-title: Wien Med Wochenschr doi: 10.1007/s10354-010-0758-5 – volume: 18 start-page: 100 issue: S5 year: 2012 ident: 10.1016/j.vaccine.2012.12.075_bib0125 article-title: Vaccines for the elderly publication-title: Clin Microbiol Infect doi: 10.1111/j.1469-0691.2012.03944.x – volume: 26 start-page: 6151 issue: 48 year: 2008 ident: 10.1016/j.vaccine.2012.12.075_bib0145 article-title: Effect of pre-existing anti-tick-borne encephalitis virus immunity on neutralising antibody response to the Vero cell-derived, inactivated Japanese encephalitis virus vaccine candidate IC51 publication-title: Vaccine doi: 10.1016/j.vaccine.2008.08.056 – volume: 353 start-page: 196 issue: 9148 year: 1999 ident: 10.1016/j.vaccine.2012.12.075_bib0165 article-title: Development of allergen-specific T-cell memory in atopic and normal children publication-title: Lancet doi: 10.1016/S0140-6736(98)05104-6 – volume: 11 start-page: 1103 issue: 9 year: 2012 ident: 10.1016/j.vaccine.2012.12.075_bib0020 article-title: Vaccines and vaccination against tick-borne encephalitis publication-title: Expert Rev Vaccines doi: 10.1586/erv.12.86 – volume: 25 start-page: 7559 issue: 43 year: 2007 ident: 10.1016/j.vaccine.2012.12.075_bib0040 article-title: Field effectiveness of vaccination against tick-borne encephalitis publication-title: Vaccine doi: 10.1016/j.vaccine.2007.08.024 – volume: 23 start-page: 427 issue: 4 year: 2004 ident: 10.1016/j.vaccine.2012.12.075_bib0070 article-title: Immunogenicity and safety of a booster vaccination against tick-borne encephalitis more than 3 years following the last immunisation publication-title: Vaccine doi: 10.1016/j.vaccine.2004.07.002 – volume: 23 start-page: 3232 issue: 25 year: 2005 ident: 10.1016/j.vaccine.2012.12.075_bib0105 article-title: Insufficient protection for healthy elderly adults by tetanus and TBE vaccines publication-title: Vaccine doi: 10.1016/j.vaccine.2005.01.085 – volume: 22 start-page: 561 issue: 3 year: 2008 ident: 10.1016/j.vaccine.2012.12.075_bib0010 article-title: Tick-borne encephalitis publication-title: Infect Dis Clin North Am doi: 10.1016/j.idc.2008.03.013 – volume: 9 start-page: 42 issue: 1 year: 1991 ident: 10.1016/j.vaccine.2012.12.075_bib0095 article-title: Humoral immunity against tick-borne encephalitis virus following manifest disease and active immunization publication-title: Vaccine doi: 10.1016/0264-410X(91)90315-W – volume: 7 start-page: 589 issue: 5 year: 2008 ident: 10.1016/j.vaccine.2012.12.075_bib0005 article-title: Advances in vaccination against tick-borne encephalitis publication-title: Expert Rev Vaccines doi: 10.1586/14760584.7.5.589 – volume: 80 start-page: 9557 issue: 19 year: 2006 ident: 10.1016/j.vaccine.2012.12.075_bib0080 article-title: Cryptic properties of a cluster of dominant flavivirus cross-reactive antigenic sites publication-title: J Virol doi: 10.1128/JVI.00080-06 – volume: 29 start-page: 7307 issue: 43 year: 2011 ident: 10.1016/j.vaccine.2012.12.075_bib0110 article-title: Prevention of tick-borne encephalitis by FSME-IMMUN vaccines: review of a clinical development programme publication-title: Vaccine doi: 10.1016/j.vaccine.2011.07.089 – volume: 27 start-page: 7027 issue: 50 year: 2009 ident: 10.1016/j.vaccine.2012.12.075_bib0060 article-title: Booster vaccinations against tick-borne encephalitis: 6 years follow-up indicates long-term protection publication-title: Vaccine doi: 10.1016/j.vaccine.2009.09.068 – volume: 24 start-page: 6808 issue: 47–48 year: 2006 ident: 10.1016/j.vaccine.2012.12.075_bib0100 article-title: Booster vaccination in the elderly: their success depends on the vaccine type applied earlier in life as well as on pre-vaccination antibody titers publication-title: Vaccine doi: 10.1016/j.vaccine.2006.06.037 – volume: 7 start-page: e34145 issue: 3 year: 2012 ident: 10.1016/j.vaccine.2012.12.075_bib0120 article-title: Age affects quantity but not quality of antibody responses after vaccination with an inactivated flavivirus vaccine against tick-borne encephalitis publication-title: PLoS ONE doi: 10.1371/journal.pone.0034145 – volume: 48 start-page: 102 issue: 1 year: 1996 ident: 10.1016/j.vaccine.2012.12.075_bib0085 article-title: Correlation between ELISA, hemagglutination inhibition, and neutralization tests after vaccination against tick-borne encephalitis publication-title: J Med Virol doi: 10.1002/(SICI)1096-9071(199601)48:1<102::AID-JMV16>3.0.CO;2-I – volume: 110 start-page: 358 issue: 3 year: 1997 ident: 10.1016/j.vaccine.2012.12.075_bib0090 article-title: Antibodies protect mice against challenge with tick-borne encephalitis virus (TBEV)-infected macrophages publication-title: Clin Exp Immunol doi: 10.1046/j.1365-2249.1997.4311446.x – volume: 24 start-page: 241 issue: 86 year: 2011 ident: 10.1016/j.vaccine.2012.12.075_bib0030 article-title: Vaccines against tick-borne encephalitis: WHO position paper publication-title: WER – volume: 25 start-page: 5097 issue: 27 year: 2007 ident: 10.1016/j.vaccine.2012.12.075_bib0075 article-title: Antibody persistence following booster vaccination against tick-borne encephalitis: 3-year post-booster follow-up publication-title: Vaccine doi: 10.1016/j.vaccine.2007.01.116 – volume: 21 start-page: S36 issue: Suppl. 1 year: 2003 ident: 10.1016/j.vaccine.2012.12.075_bib0130 article-title: Diagnosis of tick-borne encephalitis publication-title: Vaccine doi: 10.1016/S0264-410X(02)00819-8 – volume: 203 start-page: 1556 issue: 11 year: 2011 ident: 10.1016/j.vaccine.2012.12.075_bib0150 article-title: A tick-borne encephalitis vaccine based on the European prototype strain induces broadly reactive cross-neutralizing antibodies in humans publication-title: J Infect Dis doi: 10.1093/infdis/jir122 – year: 2009 ident: 10.1016/j.vaccine.2012.12.075_bib0055 article-title: Seropositivity before and seroprotection after a booster vaccination with FSME-Immun adults in subjects with a time interval of >4.5 years since the last TBE vaccination – volume: 5 start-page: 551 issue: 8 year: 2009 ident: 10.1016/j.vaccine.2012.12.075_bib0115 article-title: Seropersistence of tick-borne encephalitis antibodies, safety and booster response to FSME-IMMUN 0.5ml in adults aged 18–67 years publication-title: Hum Vaccines doi: 10.4161/hv.5.8.8571 – volume: 21 start-page: S50 issue: S 1 year: 2003 ident: 10.1016/j.vaccine.2012.12.075_bib0035 article-title: TBE vaccination and the Austrian experience publication-title: Vaccine doi: 10.1016/S0264-410X(02)00813-7 – volume: 211 start-page: 303 year: 2006 ident: 10.1016/j.vaccine.2012.12.075_bib0175 article-title: Understanding and making use of human memory B cells publication-title: Immunol Rev doi: 10.1111/j.0105-2896.2006.00403.x – ident: 10.1016/j.vaccine.2012.12.075_bib0025 doi: 10.2807/ese.14.36.19325-en – volume: 27 start-page: 853 issue: 6 year: 2009 ident: 10.1016/j.vaccine.2012.12.075_bib0065 article-title: Long-term persistence of tick-borne encephalitis antibodies in adults 5 years after booster vaccination with Encepur Adults publication-title: Vaccine doi: 10.1016/j.vaccine.2008.11.082 – volume: 24 start-page: 2781 issue: 15 year: 2006 ident: 10.1016/j.vaccine.2012.12.075_bib0140 article-title: Comparative immunogenicity of a PreS/S hepatitis B vaccine in non- and low responders to conventional vaccine publication-title: Vaccine doi: 10.1016/j.vaccine.2006.01.007 – volume: 25 start-page: 927 issue: 5 year: 2007 ident: 10.1016/j.vaccine.2012.12.075_bib0135 article-title: Persistence of seroprotection 10 years after primary hepatitis A vaccination in an unselected study population publication-title: Vaccine doi: 10.1016/j.vaccine.2006.08.044 – year: 2007 ident: 10.1016/j.vaccine.2012.12.075_bib0170 – volume: 13. issue: 26 year: 2008 ident: 10.1016/j.vaccine.2012.12.075_bib0015 article-title: Tick-borne encephalitis in Europe and beyond—the epidemiological situation as of 2007 publication-title: Euro Surveill doi: 10.2807/ese.13.26.18916-en – volume: 22 start-page: 2743 issue: 21–22 year: 2004 ident: 10.1016/j.vaccine.2012.12.075_bib0050 article-title: Persistence of protective immunity following vaccination against tick-borne encephalitis—longer than expected? publication-title: Vaccine doi: 10.1016/j.vaccine.2004.01.041 |
SSID | ssj0005319 |
Score | 2.2331774 |
Snippet | ► Tick borne encephalitis antibody titers were assessed in 178 and 183 subjects 8 and 10 years post-booster. ► Cumulative seroprotection rates were 86.8% and... Highlights ► Tick borne encephalitis antibody titers were assessed in 178 and 183 subjects 8 and 10 years post-booster. ► Cumulative seroprotection rates were... In a sample of originally 430 healthy adults (18–84 years of age) with documented basic and booster immunization against tick borne encephalitis, cumulative... In a sample of originally 430 healthy adults (18-84 years of age) with documented basic and booster immunization against tick borne encephalitis, cumulative... Highlights * Tick borne encephalitis antibody titers were assessed in 178 and 183 subjects 8 and 10 years post-booster. * Cumulative seroprotection rates were... In a sample of originally 430 healthy adults (18a84 years of age) with documented basic and booster immunization against tick borne encephalitis, cumulative... |
SourceID | proquest pubmed pascalfrancis crossref fao elsevier |
SourceType | Aggregation Database Index Database Enrichment Source Publisher |
StartPage | 1293 |
SubjectTerms | Adolescent Adult adults Age Age Factors Aged Allergies Allergy and Immunology Antibodies, Neutralizing - blood Antibodies, Viral - blood Antibody persistence antigens Applied microbiology Arachnids Arboviral encephalitis Arboviroses Biological and medical sciences Booster properties Encephalitis Encephalitis Viruses, Tick-Borne - immunology Female Fever Follow-up Fundamental and applied biological sciences. Psychology Human viral diseases Humans hypersensitivity Immune system immunity Immunization schedule Immunologic Memory Infectious diseases Ixodidae Long-term Male Medical sciences Microbiology Middle Aged Miscellaneous neutralization neutralization tests Population secondary immunization Studies Tick borne encephalitis ticks Time Factors Tropical viral diseases Vaccination - methods Vaccines Vaccines, antisera, therapeutical immunoglobulins and monoclonal antibodies (general aspects) Viral diseases Viral infections Viral Vaccines - administration & dosage Viral Vaccines - immunology Virology viruses Young Adult |
SummonAdditionalLinks | – databaseName: Elsevier ScienceDirect dbid: .~1 link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV3db9MwELfGJBAvCMrHAmMyEtrT0iaOEzuPaKKakECT1qG-WXZij2yQVk07qS_87dw5ScvE2BBSn9o71_Fd7n6274OQ9yBIHRvY5GSOFyG4AB3qtNQhx2ZwjEWSa1_t80t2cs4_TdPpDjnuc2EwrLKz_a1N99a6-2bUreZoXlWjs8j78mgagw8DXI52mHOBWj78-VuYR-KbeyBxiNTbLJ7R5fBaF3h9jRFezJ8KYrjh7f7pgdMzDJzUDayda5te_B2Veu80fkqedLCSfmhn_ozs2HpAHraNJtcD8uhzd4U-IIenbbHq9RGdbHOvmiN6SE-3ZayBZ_AVI2V8ui7t2Z-TH-O2QQ_VnVxtSfEsl4IqzyqfbLJcU32hK8CdFEa-oqBltaW4svNviPqrhl5Xi1VD44iu4UWDsbBROdBhwsmCtsvlNeYFmYw_To5Pwq5lQ1iABJZhWRY5E9bkVhgrOKAZmbhClq60LC5slDtAdMKVjBkjdKZF4crICSfTVHBjk5dkt57Vdo_QXAKWMCA2m8c81YW2iRF5xDWMoZ1hAeG9nFTRlTPHrhrfVR-3dqk68SoUr4IPiDcgww3bvK3ncR9D1iuB6pNVwbwq8Dj3MYrbGG3TGYlGxaoBSvWHIgdEbjhvvAv_8qd7oKdKX4CHUOdnDM-zwObKVMKoBzeUd_P4TMR4LpAEZL_XZrWdI-6PEwmgJSDvNj-DCcJ7JV3b2QpomMxyjpUj76BJuOQ5Fpi7gyaTGez1AFIG5FX7Nm0nmcDeNhHx6_9fmzfkMfO9TFgYy32yu1ys7FtAlEtz4E3GL-EXczo priority: 102 providerName: Elsevier |
Title | Factors associated with seroimmunity against tick borne encephalitis virus 10 years after booster vaccination |
URI | https://www.clinicalkey.com/#!/content/1-s2.0-S0264410X12018622 https://www.clinicalkey.es/playcontent/1-s2.0-S0264410X12018622 https://dx.doi.org/10.1016/j.vaccine.2012.12.075 https://www.ncbi.nlm.nih.gov/pubmed/23306371 https://www.proquest.com/docview/1625938299 https://www.proquest.com/docview/1286944475 https://www.proquest.com/docview/1348490430 https://www.proquest.com/docview/1686729415 |
Volume | 31 |
hasFullText | 1 |
inHoldings | 1 |
isFullTextHit | |
isPrint | |
link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwjV3db9MwELfoJhAvCMrHCqMyEtrT0sWOEztPaEyrCoiqYh3qm-Uk9uiAtjTtpL7wt3OXj0ZIo0Oq0krxuU7ufP75fB-EvAVGGpbAJidyIvVgCTCeCTPjCSwGx7mvhCmyfQ6jwaX4OAknlcEtr9wqa51YKOpsnqKN_IQhUA8UaM93i18eVo3C09WqhEaL7GPqMnTpkhPZuHgERWEP2GYITzB_0kTwnFz3bkyKR9fo3cULiyC6Gt6-NrWcmaPTpMnhvbmy4MW_EWmxMvUfk0cVpKSnpQw8IffsrE3ul0UmN23y4HN1fN4mR6MyUfXmmI6buKv8mB7RUZPCGmjaX9FLpgjVpTX5U_KzXxbnoabiqc0o2nEpiPF8WgSarDbUXJkpYE4KPX-nIGEzS1F7LL4h4p_m9Ga6XOeU-XQDkwz6wiLl0A6DTZa0fF2FtDwj4_75-GzgVeUavDTifOVlWRpzaZPYysRKAUhGBS5VmcssZ6n1YwdoTrqM8ySRJjIydZnvpFNhKEVig-dkbzaf2QNCYwU4IgG22ZiJ0KTGBomMfWGgD-MS3iGi5pNOq1TmWFHjh6591q51xV6N7NXwAfZ2SG9LtihzedxFENVCoOtAVVCtGlabuwjlbYQ2rxRErpnOoaW-8AtA6k8YUMPmEh5NbSkrDFRim__50wOQU22uYHXQlxccbVmgb1WooNfuX8K7fXwuGdoEgg45rKVZN2PcTrkOebO9DeoHz5TMzM7X0IarKBaYNXJHm0AoEWNyuR1tIhXBPg_gZIe8KGdTM8gA9rWBZC93D_IVeciLWiXcY-qQ7K2Wa_saEOMq6ZJW7zfrFsoBruoMfu-ffvg0GML3-_Ph6MsfqqduJA |
linkProvider | ProQuest |
linkToHtml | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV3db9MwED9tnfh4QVA-VhjDSLCnZYsdJ3YeEOJjVce2qmId6pvlJM7ogLY07VD_KP5HzvlohDQ6XiblrT7H6Z3vw767H8ArZKSmEQY5QcpjB02AdrSfaIdbMDjGXMl13u2zG3TO-KeBP1iD31UtjE2rrHRirqiTcWzPyPepddQ9idrz7eSnY1Gj7O1qBaFRiMWRWfzCkC17c_gR-fuasfZB_0PHKVEFnDhgbOYkSRwyYaLQiMgIjgZXemkskzQxjMbGDVN0OkSaMBZFQgdaxGnipiKVvi94ZDycdh02uIeRTAM23h90e5_rnBIvRxLBuIY7nLqDumRo_2LvUsf2rtymk7H8CNLmNl5tDNdTPbZZmjpDRqUFwsa_XeDcFLbvw73ShyXvCqF7AGtm1IRbBarlogm3T8r7-ibs9IrO2Itd0q8LvbJdskN6dc9spGl-sWk5eW0wqcgfwo92gQZEdClEJiH24JjgvhkP88qW2YLocz1EJ5fgzN8IivTIEKuuJl9tiDHMyOVwOs8IdckC2YdzWVR0HGerW6ak-Lty8XwE_Zvg5GNojMYjswkklOi4RMg2E1Lu61gbLxKhyzXOodOItYBXfFJx2TvdQnh8V1WS3IUq2assexU-yN4W7C3JJkXzkOsIgkoIVFUZi7pcoXm7jlBcRWiyUiNliqoMR6pTN_eA3QFFaoxm8dPkkrJ0ugpn6n9euolyqvQ5miN1dsrs4RkqeOlLnHX7L-Fdfj4T1B5CeC3YqqRZ1Wtc7vEWvFz-jPrOXmLpkRnPcQyTQchtm8oVYzwueWi72a0YE8gAA0v0X1vwpNhN9SI9DKQ9QZ-uXuQLuNPpnxyr48Pu0TO4y3KgFOZQuQWN2XRunqO7Oou2SyVBQN2wWvoDx06pTg |
linkToPdf | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV3db9MwELe2ISZeEBTYCmMYCfa0rLHjxM4DQohRbQymSutQ3ywnsUcHtKVph_qn8d9xl49GSKPjZVLf6nPt3vk-7Lv7EfIKGGlYAkFO5ETqgQkwngkz4wkEg-PcV8IU3T5Po6Nz8XEQDtbI77oWBtMqa51YKOpsnOIdeYehox4o0J4dV6VF9A67byc_PUSQwpfWGk6jFJETu_gF4Vv-5vgQeP2a8-6H_vsjr0IY8NKI85mXZWnMpU1iKxMrBRhfFbhUZS6znKXWjx04INJlnCeJNJGRqct8J50KQykSG8C06-SOhH3hEZMD2WSXBAWmCEQ4whPMHzTFQ53LgyuT4qs5Jpbx4jISsxyvN4vrzowxX9PkwDJXYm382xkujGL3AblfebP0XSl-D8maHbXI3RLfctEim5-rl_sW2euVPbIX-7TflHzl-3SP9pru2UDT-oIJOkWVMK3JH5Ef3RIXiJpKnGxG8QqZwgkaD4sal9mCmgszBHeXwszfKAj3yFJUXJOvGGwMc3o1nM5zyny6AObBXIiPDuOwzmVKy7-rENTHpH8bfHxCNkbjkd0mNFbgwiTANhszEZrU2CCRsS8MzGFcwttE1HzSadVFHcE8vus6Xe5SV-zVyF4NH2BvmxwsySZlG5GbCKJaCHRdIwtaXYOhu4lQXkdo80o35ZrpHEbqM7_whf0BA2qIa2FraklZuV-lW_U_P7oNcqrNBRgmfX7G8RoNVL0KFcy6-5fwLrfPJcPriKBNdmpp1s0al6e9TV4uvwbNh89ZZmTHcxjDVRQLbFi5YkwglIixr92KMZGKIMQET7ZNtsrT1CwygJA6kOzp6kW-IJugjPSn49OTZ-QeLxBTuMfUDtmYTef2Ofits2S30BCU6FvWSH8AlkOsHg |
openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Factors+associated+with+seroimmunity+against+tick+borne+encephalitis+virus+10+years+after+booster+vaccination&rft.jtitle=Vaccine&rft.au=PAULKE-KORINEK%2C+Maria&rft.au=KUNDI%2C+Michael&rft.au=LAABER%2C+Brigitte&rft.au=BRODTRAEGER%2C+Natascha&rft.date=2013-02-18&rft.pub=Elsevier&rft.issn=0264-410X&rft.volume=31&rft.issue=9&rft.spage=1293&rft.epage=1297&rft_id=info:doi/10.1016%2Fj.vaccine.2012.12.075&rft.externalDBID=n%2Fa&rft.externalDocID=27110613 |
thumbnail_m | http://utb.summon.serialssolutions.com/2.0.0/image/custom?url=https%3A%2F%2Fcdn.clinicalkey.com%2Fck-thumbnails%2F0264410X%2FS0264410X13X00076%2Fcov150h.gif |